The Chinese Hypertrophic Cardiomyopathy Study(CHCS)
Recruiting now
Conditions studied: Cardiomyopathy, Hypertrophic
In brief
Hypertrophic cardiomyopathy (HCM) is one of the most common inherited cardiac diseases, with a prevalence of ∼0.2%. Sudden cardiac death (SCD), heart failure and stroke are the major poor outcomes of HCM. Although about half of the patients were found to be caused by mutations mainly located in genes encoding sarcomere proteins, the causes in a significant proportion of patients with HCM are still unknown. Even in the patients with sarcomere mutations, the molecular pathways that eventually lead to cardiac hypertrophy are remained to be revealed. Furthermore, HCM presents with significant heterogeneity. SCD risk stratification and prevention by ICD are necessary. However, the strategy of SCD risk stratification recommended by the 2011 ACCF/AHA and 2014 ESC guidelines were based mainly on the evidence derived from American and European countries. The accuracy of these guidelines in Chines patients with HCM was not evaluated yet.
Key facts
- Study ID
- NCT02696135
- Run by
- China National Center for Cardiovascular Diseases
- People needed
- 3000
- Starts
- 2011-03-23
- Expected to finish
- 2028-12-31
- Last updated by the study team
- 2018-03-27
Who can join
Age: any. Sex: any. Healthy volunteers: accepted.
Where it is running
- Fuwai hospital — Beijing, Beijing Municipality, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.